Last reviewed · How we verify
Daily infusion of dornase alfa
Daily infusion of dornase alfa is a Recombinant enzyme Small molecule drug developed by Fondation Ophtalmologique Adolphe de Rothschild. It is currently in Phase 2 development for Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations).
Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance.
Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance. Used for Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations).
At a glance
| Generic name | Daily infusion of dornase alfa |
|---|---|
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Drug class | Recombinant enzyme |
| Target | Extracellular DNA |
| Modality | Small molecule |
| Therapeutic area | Pulmonary/Respiratory |
| Phase | Phase 2 |
Mechanism of action
Dornase alfa cleaves extracellular deoxyribonucleic acid (DNA) that accumulates in respiratory secretions, particularly in cystic fibrosis patients where neutrophil-derived DNA contributes to thick, sticky mucus. By degrading this DNA, the enzyme reduces sputum viscosity and elasticity, facilitating mucociliary clearance and improving airway function. This mechanism helps reduce airway obstruction and infection risk in patients with compromised lung function.
Approved indications
- Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations)
Common side effects
- Voice hoarseness
- Pharyngitis
- Laryngitis
- Chest pain
- Hemoptysis
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months (PHASE2)
- The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daily infusion of dornase alfa CI brief — competitive landscape report
- Daily infusion of dornase alfa updates RSS · CI watch RSS
- Fondation Ophtalmologique Adolphe de Rothschild portfolio CI
Frequently asked questions about Daily infusion of dornase alfa
What is Daily infusion of dornase alfa?
How does Daily infusion of dornase alfa work?
What is Daily infusion of dornase alfa used for?
Who makes Daily infusion of dornase alfa?
What drug class is Daily infusion of dornase alfa in?
What development phase is Daily infusion of dornase alfa in?
What are the side effects of Daily infusion of dornase alfa?
What does Daily infusion of dornase alfa target?
Related
- Drug class: All Recombinant enzyme drugs
- Target: All drugs targeting Extracellular DNA
- Manufacturer: Fondation Ophtalmologique Adolphe de Rothschild — full pipeline
- Therapeutic area: All drugs in Pulmonary/Respiratory
- Indication: Drugs for Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations)
- Compare: Daily infusion of dornase alfa vs similar drugs
- Pricing: Daily infusion of dornase alfa cost, discount & access